• Mashup Score: 10
    Clinical consensus guideline on the management of phaeochromocytoma and paraganglioma in patients harbouring germline SDHD pathogenic variants - 6 month(s) ago

    Patients with germline SDHD pathogenic variants (encoding succinate dehydrogenase subunit D; ie, paraganglioma 1 syndrome) are predominantly affected by head and neck paragangliomas, which, in almost 20% of patients, might coexist with paragangliomas arising from other locations (eg, adrenal medulla, para-aortic, cardiac or thoracic, and pelvic). Given the higher risk of tumour multifocality and bilaterality for phaeochromocytomas and paragangliomas (PPGLs) because of SDHD pathogenic variants than for their sporadic and other genotypic counterparts, the management of patients with SDHD PPGLs is clinically complex in terms of imaging, treatment, and management options.

    Source: www.thelancet.com
    Categories: Endocrinology, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of TheLancetEndo
      TheLancetEndo

      #Clinical #consensus #guideline on the management of #phaeochromocytoma and #paraganglioma in patients harbouring germline SDHD pathogenic variants https://t.co/PJSiZnUXga #PPGLs #FREE to read with registration (also FREE) https://t.co/Ft03vxQZwd

  • Mashup Score: 12
    Systemic Therapy for Small-Cell Lung Cancer: ASCO-Ontario Health (Cancer Care Ontario) Guideline - 7 month(s) ago

    PURPOSE To provide evidence-based recommendations to practicing clinicians on the management of patients with small-cell lung cancer. METHODS An Expert Panel of medical oncology, thoracic surgery, radiation oncology, pulmonary, community oncology, research methodology, and advocacy experts were convened to conduct a literature search, which included systematic reviews, meta-analyses, and randomized controlled trials published from 1990 through 2022. Outcomes of interest included response rates, overall survival, disease-free survival or recurrence-free survival, and quality of life. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations. RESULTS The literature search identified 95 relevant studies to inform the evidence base for this guideline. RECOMMENDATIONS Evidence-based recommendations were developed to address systemic therapy options, timing of therapy, treatment in patients who are older or with poor performance s

    Source: ascopubs.org
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of RManochakian
      RManochakian

      🔥🚨Hot off the press @JCO_ASCO NEW @ASCO & @OntarioHealthOH #Guideline on #SystemicTherapy for #SmallCell #LungCancer. I’m honored to have worked with great colleagues/experts on this guideline (evidence-based recommendations) panel. @OncoAlert #SCLC 👇🏼 https://t.co/oEAzPtTiU3 https://t.co/4QNlR7A6cU

  • Mashup Score: 0
    ENGAGE Workshop - 7 month(s) ago

    NHLBI presents the Enhancing Implementation of Guidelines and Evidence-based Care in Clinical and Community Settings (ENGAGE) Workshop

    Source: www.eventbrite.com
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of NHLBI_Translate
      NHLBI_Translate

      .@NIH: ENGAGE workshop, October 16-17, will explore factors in successful approaches for #guideline development, #implementation #dissemination and identification of priority areas! #ImpSci @ImplementSci #NHLBI #ENGAGE @Fogarty_NIH @Brian_Mittman @TCI_ca https://t.co/HBXUrKIMMC https://t.co/JGc4RTvHfR

  • Mashup Score: 0
    The adherence to and utility of the Global Initiative for Chronic Obstructive Lung Disease guidelines for treating COPD among pulmonary specialists: a retrospective analysis - BMC Pulmonary Medicine - 8 month(s) ago

    Background Despite the evidence-based guidelines promoted by the Global Initiative for Chronic Obstructive Lung Disease (GOLD), the overuse of prescription drugs to manage COPD, particularly inhaled corticosteroids (ICS), remains a persistent challenge. In this real-world study, we evaluated how patients with COPD were divided into ABCD groups based on the 2017 GOLD guidelines, determined the rate of adherence to the GOLD treatment recommendations, described the rate of ICS usage, and determined the rate of triple therapy (TT) prescription. Methods The charts of 2291 patients diagnosed with COPD were retrospectively analyzed, of which 1438 matched the eligibility criteria. Results The average patient age was 69.6 ± 10.9 years; 52% of patients were female. The average COPD assessment test (CAT) score was 18.3 ± 9.1. The ABCD breakdown was as follows: group A 19.5%, group B 64.1%, group C 1.8%, and group D 14.6%. All groups, except group D, showed discordance in COPD treatment relative t

    Source: bmcpulmmed.biomedcentral.com
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of NHLBI_Translate
      NHLBI_Translate

      Gap between #Guideline recommendations of the Global Initiative for Chronic Obstructive Lung Disease (GOLD) and real-world clinical practice in #COPD care. Need for #Implementation #ImpSci #DIRH @NIH. #Overuse of inhaled #corticosteroids; #underuse of EBIs https://t.co/Apc3ZiaJ3C https://t.co/FzwiQpm9Bh

  • Mashup Score: 3
    Clinical consensus guideline on the management of phaeochromocytoma and paraganglioma in patients harbouring germline SDHD pathogenic variants - 8 month(s) ago

    Patients with germline SDHD pathogenic variants (encoding succinate dehydrogenase subunit D; ie, paraganglioma 1 syndrome) are predominantly affected by head and neck paragangliomas, which, in almost 20% of patients, might coexist with paragangliomas arising from other locations (eg, adrenal medulla, para-aortic, cardiac or thoracic, and pelvic). Given the higher risk of tumour multifocality and bilaterality for phaeochromocytomas and paragangliomas (PPGLs) because of SDHD pathogenic variants than for their sporadic and other genotypic counterparts, the management of patients with SDHD PPGLs is clinically complex in terms of imaging, treatment, and management options.

    Source: www.thelancet.com
    Categories: Endocrinology, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of TheLancetEndo
      TheLancetEndo

      This #consensus #guideline aims to help physicians with the clinical decision-making process when caring for patients with SDHD #PPGLs https://t.co/PJSiZnVv5I #phaeochromocytomas #paragangliomas #FREE to read with registration (also FREE) https://t.co/C43GJnc1vg

  • Mashup Score: 6
    BSR pregnancy GL WG response to EMA HCQ response - 9 month(s) ago

    Mark D Russell, Mrinalini Dey, Julia Flint, Philippa Davie, Alexander Allen, Amy Crossley, Margreta Frishman, Mary Gayed, Kenneth Hodson, Munther Khamashta, Lou

    Source: academic.oup.com
    Categories: Latest Headlines, Rheumatology
    Tweet Tweets with this article
    • Profile photo of RheumJnl
      RheumJnl

      New on #AdvanceAccess: The @RheumatologyUK #guideline working group has published a letter in response to the recent #EMA safety alert on #hydroxycholoroquine in #pregnancy. Read it here 👇 https://t.co/RAapWj3htb @CarolinendLupus @DrMiniDey

  • Mashup Score: 8
    Clinical consensus guideline on the management of phaeochromocytoma and paraganglioma in patients harbouring germline SDHD pathogenic variants - 9 month(s) ago

    Patients with germline SDHD pathogenic variants (encoding succinate dehydrogenase subunit D; ie, paraganglioma 1 syndrome) are predominantly affected by head and neck paragangliomas, which, in almost 20% of patients, might coexist with paragangliomas arising from other locations (eg, adrenal medulla, para-aortic, cardiac or thoracic, and pelvic). Given the higher risk of tumour multifocality and bilaterality for phaeochromocytomas and paragangliomas (PPGLs) because of SDHD pathogenic variants than for their sporadic and other genotypic counterparts, the management of patients with SDHD PPGLs is clinically complex in terms of imaging, treatment, and management options.

    Source: www.thelancet.com
    Categories: Endocrinology, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of TheLancetEndo
      TheLancetEndo

      Clinical consensus #guideline on the management of #phaeochromocytoma and #paraganglioma in patients harbouring germline #SDHD pathogenic variants https://t.co/PJSiZnVv5I #PPGLs FREE to read with registration (also FREE)

Load More